TNF-alpha (Tumor Necrosis Factor alpha) Antibody - With BSA and Azide

Provided below are standard protocols that you may find useful for product applications.

BACKGROUND

This antibody neutralizes TNF alpha biological activities. It prevents TNF alpha induced apoptosis in Jurkat cells. It also neutralizes HurTNFamediated cytotoxicity of L929 cells and inhibits tumor growth in mice. It protects mice against toxicity of HurTNFa. Tumor Necrosis Factor Alpha (TNF alpha) is a protein secreted by lipopolysaccharide-stimulated macrophages, and causes tumor necrosis when injected into tumor bearing mice. TNF alpha is believed to mediate pathogenic shock and tissue injury associated with endotoxemia. TNF alpha exists as a multimer of two, three, or five non-covalently linked units, but shows a single 17kDa band following SDS PAGE under non-reducing conditions. TNF alpha is closely related to the 25kDa protein Tumor Necrosis Factor beta (lymphotoxin), sharing the same receptors and cellular actions. TNF alpha causes cytolysis of certain transformed cells, being synergistic with interferon gamma in its cytotoxicity. Although it has little effect on many cultured normal human cells, TNF alpha appears to be directly toxic to vascular endothelial cells. Other actions of TNF alpha include stimulating growth of human fibroblasts and other cell lines, activating polymorphonuclear neutrophils and osteoclasts, and induction of interleukin 1, prostaglandin E2 and collagenase production.

REFERENCES

McLaughlin PJ; Elwood NJ; Russell SM; Andrew SM; McKenzie IF. Properties of monoclonal antibodies to human tumor necrosis factor alpha (TNF alpha). Anticancer Research, 1992, 12(4):1243-6. | P. Vassalli, Annu Rev Immunol 10: 411-452 (1992). | M. Paparakis, et al, Cytokine and Growth Factor Reviews 7: 223-229 (1996). | A. Eigler, et al, Immunology Today 18: 487-492 (1997). | Kalli K R, Kaufmann S H, et al. Molecular Pharmacology 64(6): 1434-1443 (2003). | R. Pijnenborg, et al, Placenta 19(4): 231-239 (1998)